Hard-knock Life – still seeking buyer
This article was originally published in Clinica
Genome sequencing firm Life Technologies still hasn't found a buyer and might need to lower its expectations, in order to tempt the likes of Roche and Thermo Fisher Scientific. That is the view of Doug Schenkel, analyst at Cowen Group, who has just downgraded Life to "neutral" from his previous rating of "outperform".
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.